BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces the sale of its HySolv™ drug delivery technology to Novartis Pharma AG for an initial payment of US$0.75m and potential additional future milestone payments of up to US$9.25m. Under the terms of the agreement, Novartis acquires all of the patent rights and know how with respect to the HySolv™ drug delivery technology.
